CREB1 Knockout HAP1 Cell Line

The choice depends on whether you are studying CREB1 (cAMP response element-binding protein 1)'s role as the prototypical cAMP/PKA-responsive transcription factor or its functions in learning, memory, and metabolic gene regulation. The Knockout line is the standard tool for asking whether CREB1 is required for these processes — CREB1 is a bZIP transcription factor that binds cAMP response elements (CRE, TGACGTCA) and is phosphorylated at S133 by PKA (downstream of cAMP), CaMK, MSK1, and other kinases; phospho-S133 CREB recruits CBP/p300 coactivators to drive target gene expression including BDNF, c-FOS, NR4A1, PCK1 (gluconeogenesis), and others. Overexpression is useful for studying CREB1 gain-of-function effects. Important consideration: CREB family members (CREB1, CREM, ATF1) share substantial substrate scope as CRE-binding factors — single CREB1 knockout may show modest phenotypes in some contexts if CREM/ATF1 compensate. Rescue with wild-type, S133A (phospho-resistant, transactivation-deficient), or DNA-binding-deficient CREB1 enables comprehensive structure-function studies. The knockout is valuable for studying cAMP-PKA-CREB signaling, learning/memory biology (CREB is critical for long-term memory formation), metabolic transcription (hepatic gluconeogenesis), and emerging CREB-targeted therapeutics in cancer (CREB inhibitors XX-650-23, 666-15) and metabolic disease.

Primary applications: • cAMP-PKA-CREB signaling: forskolin/IBMX-induced phospho-CREB (S133) Western blot analysis in CREB1-null versus rescued cells. • CRE-driven transcription: CRE-luciferase reporter assays and CREB target gene (BDNF, c-FOS, NR4A1, PCK1) expression analysis. • Learning/memory studies: in heterologous neural-relevant contexts, characterization of CREB1's role in BDNF induction. • Hepatic gluconeogenesis: in heterologous hepatocyte-relevant contexts, glucagon/cAMP-induced PCK1, G6PC expression. • CREB inhibitor specificity: critical genetic control for XX-650-23, 666-15, and other emerging CREB-targeted compounds in cancer drug development. EDITGENE recommends this model for researchers investigating cAMP-PKA-CREB signaling, transcriptional regulation in learning/memory and metabolism, and CREB-targeted therapeutic development.

Yes. CREB1 rescue experiments are well-established for transcription factor research: • Construct design: use a codon-modified CREB1 sequence with a small C-terminal tag (FLAG, HA). CREB1 has N-terminal Q1 (glutamine-rich) domain, KID (kinase-inducible domain, with S133 phospho-site), Q2 domain, and C-terminal bZIP (basic region + leucine zipper, DNA binding) — preserve all elements. • Phospho-resistant rescue: S133A mutation abolishes PKA/CaMK/MSK1-mediated phosphorylation and CBP/p300 recruitment, generating signal-insensitive CREB1. • Phospho-mimetic rescue: S133D/E mutations partially mimic phospho-CREB to test constitutively active transcription. • DNA-binding-deficient rescue: bZIP basic region mutations abolish CRE binding without affecting dimerization. • Functional readout: rescue should restore cAMP-induced CRE-reporter activity and target gene (BDNF, c-FOS) induction. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.